Abstract
Metabolic myopathies are among the treatable causes of rhabdomyolysis and myoglobinuria. Carnitine palmitoyl transferase 2 (CPT II) deficiency is one of the most common causes of recurrent myoglobinuria in adults. It is an inherited disorder of fatty acid oxidation pathway, commonly associated with elevated acylcarnitine levels. In this case report, we present a 49-year-old male patient who developed acute kidney injury after rhabdomyolysis and was thus diagnosed with CPT2 deficiency after his first episode of rhabdomyolysis. Inborn errors of metabolism should be kept in mind in patients with rhabdomyolysis. Acylcarnitine profile may be normal in CPT II deficiency, even during an acute attack, and molecular genetic diagnostics should be applied if there is high index of clinical suspicion.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
All data underlying the results are available as part of the article and no additional source data are required.
References
Thuillier L, et al. Correlation between genotype, metabolic data, and clinical presentation in carnitine palmitoyltransferase 2 (CPT2) deficiency. Hum Mutat. 2003;21(5):493–501.
Oey NA, et al. Long-chain fatty acid oxidation during early human development. Pediatr Res. 2005;57(6):755–9.
Houten SM, Wanders RJ. A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation. J Inherit Metab Dis. 2010;33(5):469–77.
Bonnefont J-P, et al. Carnitine palmitoyltransferase deficiencies. Mol Genet Metab. 1999;68(4):424–40.
Longo, N., C. Amat di San Filippo, and M. Pasquali. Disorders of carnitine transport and the carnitine cycle. in American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 2006. Wiley Online Library
Zach C, et al. Unrecognized high occurrence of genetically confirmed hereditary carnitine palmitoyltransferase II deficiency in an Austrian family points to the ongoing underdiagnosis of the disease. Front Genet. 2019;10:497.
Angelini C, et al. Metabolic lipid muscle disorders: biomarkers and treatment. Ther Adv Neurol Disord. 2019;12:1756286419843359.
Joshi PR, Zierz S. Muscle carnitine palmitoyltransferase II (CPT II) deficiency: a conceptual approach. Molecules. 2020;25(8):1784.
Mador-House R, Liu Z, Dyack S. Detection of early onset carnitine palmitoyltransferase II deficiency by newborn screening: should CPT II deficiency be a primary disease target? Int J Neonatal Screen. 2021;7(3):55.
Ambrose A, et al. Outcomes of mitochondrial long chain fatty acid oxidation and carnitine defects from a single center metabolic genetics clinic. Orphanet J Rare Dis. 2022;17(1):1–14.
Vockley J, et al. OP017: triheptanoin for the treatment of long-chain fatty acid disorders (LC-FAOD): final results of an open-label, long-term extension study. Genet Med. 2022;24(3):S349.
Melone MAB, et al. The carnitine system and cancer metabolic plasticity. Cell Death Dis. 2018;9(2):228.
Edmondson AC, et al. Missed newborn screening case of carnitine palmitoyltransferase-II deficiency. JIMD Rep. 2017;33:93–7.
Fontaine M, et al. Fluxomic assay-assisted diagnosis orientation in a cohort of 11 patients with myopathic form of CPT2 deficiency. Mol Genet Metab. 2018;123(4):441–8.
Tarnopolsky MA. Metabolic myopathies. Contınuum. 2016;22(6):1829–51.
Nance JR, Mammen AL. Diagnostic evaluation of rhabdomyolysis. Muscle Nerve. 2015;51(6):793–810.
Izumi R, et al. A case of late onset riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency manifesting as recurrent rhabdomyolysis and acute renal failure. Intern Med. 2011;50(21):2663–8.
Antunes AP, et al. Intermittent rhabdomyolysis with adult onset associated with a mutation in the ACADVL gene. J Clin Neuromuscul Dis. 2013;15(2):69–72.
Fuseya Y, et al. Adult-onset repeat rhabdomyolysis with a very long-chain acyl-CoA dehydrogenase deficiency due to compound heterozygous ACADVL mutations. Intern Med. 2020;59(21):2729–32.
Berardo A, DiMauro S, Hirano M. A diagnostic algorithm for metabolic myopathies. Curr Neurol Neurosci Rep. 2010;10:118–26.
Thomas-Wilson A, et al. Whole-exome sequencing detects PYGM variants in two adults with McArdle disease. Mole Case Studies. 2022;8(2): a006173.
Zhao X, et al. McArdle disease: a “pediatric” disorder presenting in an adult with acute kidney injury. CEN Case Rep. 2017;6:156–60.
Toscano A, Barca E, Musumeci O. Update on diagnostics of metabolic myopathies. Curr Opin Neurol. 2017;30(5):553–62.
Nagappa M, Narayanappa G. Approach to the diagnosis of metabolic myopathies. Indian J Pathol Microbiol. 2022;65(5):277.
Finsterer J. Update review about metabolic myopathies. Life. 2020;10(4):43.
Funding
The study did not receive funding.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Akar, H.T., Yıldız, Y., Mutluay, R. et al. Adult-onset carnitine palmitoyl transferase II (CPT II) deficiency presenting with rhabdomyolysis and acute kidney injury. CEN Case Rep 13, 81–85 (2024). https://doi.org/10.1007/s13730-023-00804-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13730-023-00804-8